{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:31:55Z","timestamp":1781883115247,"version":"3.54.5"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T00:00:00Z","timestamp":1608768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["204928\/Z\/16\/Z"],"award-info":[{"award-number":["204928\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["20fk0108085j0002"],"award-info":[{"award-number":["20fk0108085j0002"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In a blinded phase 1 trial (EudraCT 2017-0000908-21; NCT03430349) in Belgium, healthy adults (aged 18\u201350 years) previously immunized exclusively with inactivated poliovirus vaccine were administered a single dose of 1 of 2 novel type 2 oral poliovirus vaccines (nOPV2-c1: S2\/cre5\/S15domV\/rec1\/hifi3 (n\u2005=\u200515); nOPV2-c2: S2\/S15domV\/CpG40 (n\u2005=\u200515)) and isolated for 28 days in a purpose-built containment facility. Using stool samples collected near days 0, 14, 21, and 28, we evaluated intestinal neutralization and immunoglobulin A responses to the nOPV2s and found that nOPV2-c1 and nOPV2-c2 induced detectable poliovirus type 2\u2013specific intestinal neutralizing responses in 40.0% and 46.7% of participants, respectively.<\/jats:p>","DOI":"10.1093\/infdis\/jiaa783","type":"journal-article","created":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T07:52:34Z","timestamp":1608364354000},"page":"287-291","source":"Crossref","is-referenced-by-count":7,"title":["Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium"],"prefix":"10.1093","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-2288","authenticated-orcid":false,"given":"Elizabeth B","family":"Brickley","sequence":"first","affiliation":[{"name":"Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth I","family":"Connor","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dartmouth-Hitchcock Medical Center , Lebanon, New Hampshire , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Wieland-Alter","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dartmouth-Hitchcock Medical Center , Lebanon, New Hampshire , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A","family":"Weiner","sequence":"additional","affiliation":[{"name":"Thayer School of Engineering, Dartmouth College , Hanover, New Hampshire , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E","family":"Ackerman","sequence":"additional","affiliation":[{"name":"Thayer School of Engineering, Dartmouth College , Hanover, New Hampshire , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minetaro","family":"Arita","sequence":"additional","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Gast","sequence":"additional","affiliation":[{"name":"PATH , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"De Coster","sequence":"additional","affiliation":[{"name":"Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp , Antwerp , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Van Damme","sequence":"additional","affiliation":[{"name":"Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp , Antwerp , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda S","family":"Bandyopadhyay","sequence":"additional","affiliation":[{"name":"Bill & Melinda Gates Foundation , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dartmouth-Hitchcock Medical Center , Lebanon, New Hampshire , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,24]]},"reference":[{"key":"2022082412282011300_CIT0001","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S1473-3099(16)30169-4","article-title":"Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants","volume":"16","author":"Wright","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2022082412282011300_CIT0002","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/cid\/ciy603","article-title":"Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine\/bivalent oral polio vaccine and trivalent inactivated polio vaccine-only immunization schedules: analysis of an open-label, randomized, controlled trial in Chilean infants","volume":"67","author":"Brickley","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022082412282011300_CIT0003","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/infdis\/jix556","article-title":"Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants previously immunized with bivalent OPV and either high-dose or standard inactivated polio vaccine","volume":"217","author":"Brickley","year":"2018","journal-title":"J Infect Dis"},{"key":"2022082412282011300_CIT0004","doi-asserted-by":"crossref","first-page":"e001613","DOI":"10.1136\/bmjgh-2019-001613","article-title":"Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden","volume":"4","author":"Brickley","year":"2019","journal-title":"BMJ Glob Health"},{"key":"2022082412282011300_CIT0005","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S1473-3099(19)30301-9","article-title":"Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis","volume":"19","author":"Macklin","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2022082412282011300_CIT0006","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/infdis\/jiaa390","article-title":"A randomized phase 4 study of immunogenicity and safety after monovalent oral type 2 Sabin poliovirus vaccine challenge in children vaccinated with inactivated poliovirus vaccine in Lithuania","volume":"223","author":"Bandyopadhyay","year":"2021","journal-title":"J Infect Dis"},{"key":"2022082412282011300_CIT0007","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study","volume":"394","author":"Van Damme","year":"2019","journal-title":"Lancet"},{"key":"2022082412282011300_CIT0008","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2217\/fmb-2019-0196","article-title":"Poliopolis: pushing boundaries of scientific innovations for disease eradication","volume":"14","author":"Van Damme","year":"2019","journal-title":"Future Microbiol"},{"key":"2022082412282011300_CIT0009","first-page":"145","volume-title":"Poliovirus. Methods in Molecular Biology, Vol. 1387","author":"Weldon","year":"2016"},{"key":"2022082412282011300_CIT0010","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1128\/JCM.00702-09","article-title":"Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues","volume":"47","author":"Kilpatrick","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2022082412282011300_CIT0011","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1128\/CVI.05225-11","article-title":"Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum","volume":"18","author":"Arita","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"2022082412282011300_CIT0012","doi-asserted-by":"crossref","first-page":"e1002599","DOI":"10.1371\/journal.ppat.1002599","article-title":"Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge","volume":"8","author":"Hird","year":"2012","journal-title":"PLoS Pathog"},{"key":"2022082412282011300_CIT0013","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/infdis\/jis241","article-title":"Waning intestinal immunity after vaccination with oral poliovirus vaccines in India","volume":"205","author":"Grassly","year":"2012","journal-title":"J Infect Dis"},{"key":"2022082412282011300_CIT0014","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.4049\/jimmunol.162.8.5011","article-title":"Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus","volume":"162","author":"Herremans","year":"1999","journal-title":"J Immunol"},{"key":"2022082412282011300_CIT0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S0022172400055133","article-title":"The response to oral poliovaccine in persons aged 16-18 years","volume":"76","author":"Smith","year":"1976","journal-title":"J Hyg (Lond)"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa783\/36157675\/jiaa783.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/2\/287\/45507723\/jiaa783.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/2\/287\/45507723\/jiaa783.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T17:23:47Z","timestamp":1697390627000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/2\/287\/6046404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,24]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,12,24]]},"published-print":{"date-parts":[[2022,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa783","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,15]]},"published":{"date-parts":[[2020,12,24]]}}}